An 8 Week Randomized, Double-Blind, Parallel Group, Multi-Center, Active Controlled Study to Evaluate the Antihypertensive Efficacy and Safety of Aliskiren Administered in Combination With Valsartan Versus Valsartan Alone in Patients With Stage 2 Systolic Hypertension and Type 2 Diabetes Mellitus.

Trial Profile

An 8 Week Randomized, Double-Blind, Parallel Group, Multi-Center, Active Controlled Study to Evaluate the Antihypertensive Efficacy and Safety of Aliskiren Administered in Combination With Valsartan Versus Valsartan Alone in Patients With Stage 2 Systolic Hypertension and Type 2 Diabetes Mellitus.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Feb 2013

At a glance

  • Drugs Aliskiren/valsartan (Primary) ; Valsartan
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Acronyms ViVID
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 22 May 2012 Results presented at the 27th Annual Scientific Meeting of the American Society of Hypertension.
    • 03 May 2012 Actual patient number 998 added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top